BidaskClub lowered shares of Invitae Corporation (NYSE:NVTA) from a sell rating to a strong sell rating in a research report released on Wednesday morning.

A number of other brokerages also recently weighed in on NVTA. Zacks Investment Research downgraded shares of Invitae Corporation from a hold rating to a sell rating in a research report on Tuesday, July 18th. J P Morgan Chase & Co reaffirmed an overweight rating and set a $15.00 price objective (up previously from $14.00) on shares of Invitae Corporation in a research report on Wednesday, August 9th. Finally, Leerink Swann lowered their price objective on shares of Invitae Corporation from $14.00 to $12.00 and set an outperform rating for the company in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $13.50.

Shares of Invitae Corporation (NYSE:NVTA) traded up $0.07 during trading hours on Wednesday, hitting $8.26. 514,882 shares of the company were exchanged, compared to its average volume of 125,296. The company has a quick ratio of 4.39, a current ratio of 2.61 and a debt-to-equity ratio of 0.33. Invitae Corporation has a twelve month low of $2.35 and a twelve month high of $8.46.

WARNING: “Invitae Corporation (NVTA) Cut to “Strong Sell” at BidaskClub” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/18/invitae-corporation-nvta-cut-to-strong-sell-at-bidaskclub.html.

Several large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC grew its position in Invitae Corporation by 190.1% in the 3rd quarter. Perceptive Advisors LLC now owns 1,884,500 shares of the medical research company’s stock worth $17,657,000 after purchasing an additional 1,235,000 shares during the last quarter. Orbimed Advisors LLC grew its position in Invitae Corporation by 232.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,518,197 shares of the medical research company’s stock worth $14,226,000 after purchasing an additional 1,061,531 shares during the last quarter. Ark Investment Management LLC grew its position in Invitae Corporation by 30.4% in the 2nd quarter. Ark Investment Management LLC now owns 982,170 shares of the medical research company’s stock worth $9,390,000 after purchasing an additional 229,189 shares during the last quarter. State Street Corp grew its position in Invitae Corporation by 43.1% in the 2nd quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock worth $5,528,000 after purchasing an additional 174,016 shares during the last quarter. Finally, Northern Trust Corp grew its position in Invitae Corporation by 39.0% in the 2nd quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock worth $4,140,000 after purchasing an additional 121,409 shares during the last quarter. 58.00% of the stock is owned by institutional investors and hedge funds.

Invitae Corporation Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Stock Ratings for Invitae Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae Corporation and related stocks with our FREE daily email newsletter.